Sanofi (NASDAQ:SNY) Receives Average Recommendation of “Moderate Buy” from Analysts

Sanofi (NASDAQ:SNY) has received an average rating of “Moderate Buy” from the five analysts that are covering the company, MarketBeat Ratings reports. Three equities research analysts have rated the stock with a hold recommendation, one has issued a buy recommendation and one has given a strong buy recommendation to the company. The average twelve-month target price among brokerages that have updated their coverage on the stock in the last year is $57.50.

Several research firms have commented on SNY. Citigroup raised shares of Sanofi to a “strong-buy” rating in a research note on Tuesday. Argus upped their price target on shares of Sanofi from $55.00 to $60.00 and gave the company a “buy” rating in a report on Friday, July 26th. Finally, StockNews.com raised shares of Sanofi from a “buy” rating to a “strong-buy” rating in a research note on Friday.

Sanofi Stock Performance

NASDAQ SNY opened at $57.63 on Friday. The stock has a market capitalization of $145.96 billion, a PE ratio of 28.96, a P/E/G ratio of 1.62 and a beta of 0.60. Sanofi has a 1-year low of $42.63 and a 1-year high of $58.97. The business has a 50 day simple moving average of $54.34 and a two-hundred day simple moving average of $50.48. The company has a debt-to-equity ratio of 0.17, a current ratio of 1.00 and a quick ratio of 0.65.

Sanofi (NASDAQ:SNY) last announced its earnings results on Thursday, July 25th. The company reported $0.93 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.88 by $0.05. The firm had revenue of $10.75 billion for the quarter, compared to analysts’ expectations of $16.86 billion. Sanofi had a net margin of 9.60% and a return on equity of 26.29%. The business’s revenue was up 7.8% compared to the same quarter last year. During the same period in the prior year, the company earned $0.95 EPS. On average, research analysts predict that Sanofi will post 4.25 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in SNY. Barrow Hanley Mewhinney & Strauss LLC lifted its holdings in Sanofi by 113.8% during the 2nd quarter. Barrow Hanley Mewhinney & Strauss LLC now owns 5,943,547 shares of the company’s stock valued at $288,381,000 after buying an additional 3,164,092 shares in the last quarter. Magnetar Financial LLC raised its stake in shares of Sanofi by 1,153.1% during the second quarter. Magnetar Financial LLC now owns 2,506,286 shares of the company’s stock valued at $121,605,000 after acquiring an additional 2,306,286 shares in the last quarter. Bank of New York Mellon Corp raised its stake in shares of Sanofi by 19.0% during the second quarter. Bank of New York Mellon Corp now owns 8,594,740 shares of the company’s stock valued at $417,017,000 after acquiring an additional 1,370,232 shares in the last quarter. Mondrian Investment Partners LTD boosted its holdings in shares of Sanofi by 43.1% in the first quarter. Mondrian Investment Partners LTD now owns 3,951,089 shares of the company’s stock valued at $192,023,000 after purchasing an additional 1,190,141 shares during the period. Finally, Armistice Capital LLC bought a new position in Sanofi in the fourth quarter worth approximately $51,520,000. 10.04% of the stock is currently owned by institutional investors.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.